StreetInsider.com News Articles

Shattuck Labs Announces Two Poster Presentations at UEG Week 2026

Tue, 13 Oct 2026 08:00:00 -0400

AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced two upcoming poster presentations at United European Gastroenterology (UEG) Week 2026, taking place October 17–20, 2026, in Barcelona, Spain.

Presentation Details

Format: Moderated poster presentation
Title: Development and Characterization of SL-846: A Half-Life Extended, Dual-Receptor (DR3 x IL23RA) Targeting Bispecific Antibody
Presenter: Mahmud Hussain, Ph.D., Director, R&D of

Shattuck Labs Announces Two Poster Presentations at UEG Week 2026

Tue, 13 Oct 2026 08:00:00 -0400

Presentation Details

UBS Starts Shattuck Labs (STTK) at Buy

Mon, 12 Oct 2026 02:23:08 -0400

UBS analyst Alice Nettleton initiates coverage on Shattuck Labs (NASDAQ: STTK) with a Buy rating and a price target of $17.00.

The analyst comments: “We initiate coverage of Shattuck Labs (STTK) with a Buy rating and a $17 PT. Our work suggests STTK's lead asset, SL-325, may offer a meaningful advantage over firstgeneration TL1A antibodies by avoiding the anti-drug antibody (ADA) liabilities that could prove to be the Achilles' heel of the TL1A class. Despite lagging peers in IBD development, we believe STTK could overcome its late start if this advantage translates into superior efficacy and durability. Upcoming TL1A Phase 3

UBS Starts Shattuck Labs (STTK) at Buy

Mon, 12 Oct 2026 02:23:08 -0400

UBS analyst Alice Nettleton initiates coverage on Shattuck Labs (NASDAQ: STTK) with a Buy rating and a price target of $17.00.

Shattuck Labs (STTK) PT Raised to $19 at Needham

Fri, 02 Oct 2026 07:05:23 -0400

(Updated - October 2, 2026 7:05 AM EDT)

Needham analyst Joseph Stringer raised the price target on Shattuck Labs (NASDAQ: STTK) to $19.00 (from $17.00) while maintaining a Buy rating.

The analyst commented: "We caught up with STTK mgmt yesterday after they announced the planned start of a Ph2 trial in hidradenitis suppurativa (HS) for its anti-DR3 mAb SL-325 (currently in Ph2b for Crohn's). Mgmt is guiding for a trial start in 4Q26 w/ topline data in 1H28. STTK previously hinted at new I&I indications for SL-325 due to the success of the TL1A class in multiple I&I indications (DR3 is the

Shattuck Labs (STTK) PT Raised to $19 at Needham

Fri, 02 Oct 2026 07:05:23 -0400

(Updated - October 2, 2026 7:05 AM EDT)

Needham analyst Joseph Stringer raised the price target on Shattuck Labs (NASDAQ: STTK) to $19.00 (from $17.00) while maintaining a Buy rating.

Shattuck Labs plans Phase 2 HS trial of SL-325, names clinical SVP

Thu, 01 Oct 2026 07:00:27 -0400

Shattuck Labs, Inc. (NASDAQ: STTK) announced plans to evaluate its drug candidate SL-325 in a Phase 2 clinical trial targeting moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease. The company also named Shoba Ravichandran, M.D., as Senior Vice President of Clinical Development, according to a press release.

The trial, called RECEPTIVE-HS1, is designed as a randomized, double-blind, placebo-controlled study expected to enroll approximately 150 patients. Initiation is planned for 2026, with data from the 16-week treatment period expected in the first half of 2028. Patients will be randomized 1:1:1 to receive a low dose of SL-325, a high

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

Thu, 01 Oct 2026 07:00:00 -0400

– RECEPTIVE-HS1 Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa (HS) expected to initiate in 2026; data from the 16-week treatment period expected in the first half of 2028 –

– HS is the second Phase 2 indication for SL-325 and expands development beyond IBD –

– Announces appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development; Dr. Ravichandran to lead the HS clinical development program –

– Cash runway guidance remains unchanged, with existing cash expected to fund operations into 2029 –

AUSTIN, TX

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

Thu, 01 Oct 2026 07:00:00 -0400

– HS is the second Phase 2 indication for SL-325 and expands development beyond IBD –

– Announces appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development; Dr. Ravichandran to lead the HS clinical development program –

– Cash runway guidance remains unchanged, with existing cash expected to fund operations into 2029 –

AUSTIN, TX

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

Wed, 02 Sep 2026 16:05:00 -0400

AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences:

Conference Details

Wells Fargo 21^st Annual Healthcare Conference

Format: Fireside chat and one-on-one meetings
Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer
Additional Management Participant: Andrew Neill, M.B.A., Chief Financial Officer
Presentation Date:

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

Wed, 02 Sep 2026 16:05:00 -0400

Conference Details

Wells Fargo 21^st Annual Healthcare Conference

Raymond James Starts Shattuck Labs (STTK) at Strong Buy

Mon, 24 Aug 2026 06:06:13 -0400

Raymond James analyst Martin Auster initiates coverage on Shattuck Labs (NASDAQ: STTK) with a Strong Buy rating and a price target of $18.00.

The analyst comments "We initiate coverage of Shattuck Labs (STTK) with a Strong Buy rating and an $18 target price. As the first and only antibody in clinic targeting the DR3 receptor, we think SL-325 could build on the success of the TL1A class within a >$20B global UC/CD market (and growing), along with significant expansion potential in derm and rheum indications. SL-325 may have competitive advantages over TL1A antibodies via potentially reduced immunogenicity and targeting of the

Raymond James Starts Shattuck Labs (STTK) at Strong Buy

Mon, 24 Aug 2026 06:06:13 -0400

Raymond James analyst Martin Auster initiates coverage on Shattuck Labs (NASDAQ: STTK) with a Strong Buy rating and a price target of $18.00.

TD Cowen Assumes Shattuck Labs (STTK) at Buy

Sat, 22 Aug 2026 07:55:11 -0400

TD Cowen analyst Stacy Ku assumes coverage on Shattuck Labs (NASDAQ: STTK) with a Buy rating.

For an analyst ratings summary and ratings history on Shattuck Labs click here. For more ratings news on Shattuck Labs click here.

Shares of Shattuck Labs closed at $7.53 yesterday.

Form SCHEDULE 13G/A Shattuck Labs, Inc. Filed by: T. Rowe Price Investment Management, Inc.

Fri, 14 Aug 2026 10:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26926679.html

Form SCHEDULE 13G/A Shattuck Labs, Inc. Filed by: T. Rowe Price Investment Management, Inc.

Fri, 14 Aug 2026 10:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26926679.html

Shattuck Labs (STTK) PT Lowered to $14 at H.C. Wainwright

Wed, 12 Aug 2026 07:27:15 -0400

(Updated - August 12, 2026 7:27 AM EDT)

H.C. Wainwright analyst Joseph Pantginis lowered the price target on Shattuck Labs (NASDAQ: STTK) to $14.00 (from $18.00) while maintaining a Buy rating.

The analyst commented: "Shattuck announced 2Q26 financial results on August 11. During the quarter, the company made significant progress in advancing its lead asset, SL-325, building on the Phase 1 healthy volunteer data reported in June, which demonstrated a best-in-mechanism immunogenicity profile, durable DR3 blockade, and a favorable safety profile, into a confirmed lead indication in Crohn's disease, with the RECEPTIVE-CD1 Phase 2b design expanded to a three-dose, ~232-patient structure from

Shattuck Labs (STTK) PT Lowered to $14 at H.C. Wainwright

Wed, 12 Aug 2026 07:27:15 -0400

(Updated - August 12, 2026 7:27 AM EDT)

H.C. Wainwright analyst Joseph Pantginis lowered the price target on Shattuck Labs (NASDAQ: STTK) to $14.00 (from $18.00) while maintaining a Buy rating.

Form S-8 Shattuck Labs, Inc.

Tue, 11 Aug 2026 07:39:00 -0400

si-local-file:///var/storage/secattach/20260811/26901499.html

Form S-8 Shattuck Labs, Inc.

Tue, 11 Aug 2026 07:39:00 -0400

si-local-file:///var/storage/secattach/20260811/26901499.html

Form 8-K Shattuck Labs, Inc. For: Aug 11

Tue, 11 Aug 2026 06:59:00 -0400

si-local-file:///var/storage/secattach/20260811/26900997.html

Form 8-K Shattuck Labs, Inc. For: Aug 11

Tue, 11 Aug 2026 06:59:00 -0400

si-local-file:///var/storage/secattach/20260811/26900997.html

Form 10-Q Shattuck Labs, Inc. For: Jun 30

Tue, 11 Aug 2026 06:57:00 -0400

si-local-file:///var/storage/secattach/20260811/26900982.html

Form 10-Q Shattuck Labs, Inc. For: Jun 30

Tue, 11 Aug 2026 06:57:00 -0400

si-local-file:///var/storage/secattach/20260811/26900982.html

Shattuck Labs, Inc. (STTK) Tops Q2 EPS by 1c

Tue, 11 Aug 2026 06:37:41 -0400

Shattuck Labs, Inc. (NASDAQ: STTK) reported Q2 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13).

For earnings history and earnings-related data on Shattuck Labs, Inc. (STTK) click here.